Table 1.

Results of in vivo anti-inflammatory activity of isoxazole derivative (5a-5m) using a carrageenan-induced paw edema model.

Treatments	Dose (mg/kg)	Increase in Paw Volume (mm)		% Inhibition		Effectiveness
		upon 2h	upon 3h	upon 2h	upon 3h
5a	100	0.54 ± 0.03	0.54 ± 0.03 ∗∗∗	45.92	46.32	0.56
5b	100	0.35 ± 0.02 ∗∗∗	0.34 ± 0.02 ∗∗∗	75.68	76.71	0.83
5c	100	0.36 ± 0.02 ∗∗∗	0.37 ± 0.02 ∗∗∗	74.48	75.56	0.81
5d	100	0.43 ± 0.01 ∗∗∗	0.43 ± 0.02 ∗∗∗	71.86	72.32	0.71
5e	100	0.82 ± 0.07	0.85 ± 0.06	13.48	11.89	0.16
5f	100	0.46 ± 0.04 ∗∗∗	0.46 ± 0.05 ∗∗∗	51.31	51.89	0.66
5g	100	0.78 ± 0.04 ∗	0.79 ± 0.04 ∗	17.68	17.41	0.22
5h	100	0.91 ± 0.04	0.95 ± 0.03	12.30	11.92	0.02
5i	100	0.57 ± 0.02 ∗∗∗	0.51 ± 0.03 ∗∗∗	39.4	46.37	0.55
5j	100	0.36 ± 0.02 ∗∗∗	0.36 ± 02 ∗∗∗	61.34	62.24	0.80
5k	100	0.88 ± 0.01	0.89 ± 0.09	7.36	7.06	0.09
5l	100	0.53 ± 0.03	0.53 ± 0.03 ∗∗∗	43.94	44.32	0.57
5m	100	0.49 ± 0.02 ∗∗∗	0.48 ± 0.02 ∗∗∗	47.81	50.34	0.63
Diclofenac sodium	10	0.21 ± 0.02 ∗∗∗	0.23 ± 0.02 ∗∗∗	74.22	73.62	1
Control Group	100	0.94 ± 0.02	0.95 ± 0.02

All results are mean SEM. ∗p 0.05, ∗∗p 0.01, ∗∗∗p 0.001; ANOVA, followed by Dunnett^, s multiple comparion test (n = 6). All results were compared to that of the control group.